Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by George Bondi on Aug 31st, 2026

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $55.00.

A number of brokerages recently commented on FTH. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Finally, Needham & Company LLC began coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective on the stock.

Read Our Latest Stock Report on Sensei Biotherapeutics

Sensei Biotherapeutics Price Performance

Shares of FTH opened at $33.84 on Monday. The company has a fifty day moving average price of $28.53. The company has a market cap of $874.43 million, a price-to-earnings ratio of -0.24 and a beta of -0.25. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, equities analysts forecast that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brian C. Stephenson acquired 9,391 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was acquired at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. This trade represents a 53.93% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of Sensei Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the period. Bank of America Corp DE grew its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter worth $3,610,000. Finally, Vivo Capital LLC bought a new position in Sensei Biotherapeutics during the first quarter worth about $22,758,000. 10.50% of the stock is owned by institutional investors.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.